These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 29698726

  • 1. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC.
    J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J, Kutter JP, Mu H, Moodley A, Yang M.
    Int J Pharm; 2020 Nov 30; 590():119877. PubMed ID: 32927003
    [Abstract] [Full Text] [Related]

  • 3. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
    Ye T, Sun S, Sugianto TD, Tang P, Parumasivam T, Chang YK, Astudillo A, Wang S, Chan HK.
    Int J Pharm; 2018 Dec 01; 552(1-2):130-138. PubMed ID: 30267753
    [Abstract] [Full Text] [Related]

  • 4. Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.
    Sommerfeld Ross S, Gharse S, Sanchez L, Fiegel J.
    Int J Pharm; 2017 Oct 05; 531(1):14-23. PubMed ID: 28826725
    [Abstract] [Full Text] [Related]

  • 5. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT, Sun SP, Chan JG, Wang P, Barraud N, Rice SA, Wang J, Li J, Chan HK.
    Mol Pharm; 2015 Aug 03; 12(8):2594-603. PubMed ID: 25423590
    [Abstract] [Full Text] [Related]

  • 6. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
    Tewes F, Bahamondez-Canas TF, Moraga-Espinoza D, Smyth HDC, Watts AB.
    Eur J Pharm Biopharm; 2020 Jul 02; 152():210-217. PubMed ID: 32442738
    [Abstract] [Full Text] [Related]

  • 8. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J, Guo Y, Lu W, Liu X, Zhang J, Sun J, Chai G.
    Int J Pharm; 2024 Jun 10; 658():124208. PubMed ID: 38723731
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.
    Eur J Pharm Biopharm; 2019 Sep 10; 142():543-552. PubMed ID: 31398437
    [Abstract] [Full Text] [Related]

  • 11. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X, Vogt FG, Hayes D, Mansour HM.
    Eur J Pharm Sci; 2014 Feb 14; 52():191-205. PubMed ID: 24215736
    [Abstract] [Full Text] [Related]

  • 12. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N, Ofosu Kissi E, Elgaher WAM, Sigal V, Haupenthal J, Schwarz BC, Hirsch AKH, Rades T, Schneider M.
    J Control Release; 2019 Nov 28; 314():62-71. PubMed ID: 31654686
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of Excipients on the Antimicrobial Activity of Tobramycin Against Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas T, Smyth HDC.
    Pharm Res; 2018 Jan 02; 35(1):10. PubMed ID: 29294187
    [Abstract] [Full Text] [Related]

  • 15. The effect of particle size of inhaled tobramycin dry powder on the eradication of Pseudomonas aeruginosa biofilms.
    Aljalamdeh R, Price R, Jones MD, Bolhuis A.
    Eur J Pharm Sci; 2021 Mar 01; 158():105680. PubMed ID: 33346008
    [Abstract] [Full Text] [Related]

  • 16. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
    Yu H, Teo J, Chew JW, Hadinoto K.
    Int J Pharm; 2016 Feb 29; 499(1-2):38-46. PubMed ID: 26757148
    [Abstract] [Full Text] [Related]

  • 17. Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin.
    Marshall LJ, Oguejiofor W, Price R, Shur J.
    Int J Pharm; 2016 Dec 05; 514(2):399-406. PubMed ID: 27628783
    [Abstract] [Full Text] [Related]

  • 18. Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process.
    Farhangi M, Mahboubi A, Kobarfard F, Vatanara A, Mortazavi SA.
    Pharm Dev Technol; 2019 Jun 05; 24(5):584-592. PubMed ID: 30431373
    [Abstract] [Full Text] [Related]

  • 19. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B, Cusimano MG, Schillaci D, Craparo EF, Giammona G, Cavallaro G.
    Biomacromolecules; 2017 Dec 11; 18(12):3924-3935. PubMed ID: 29111673
    [Abstract] [Full Text] [Related]

  • 20. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
    Pilcer G, Vanderbist F, Amighi K.
    J Pharm Sci; 2009 Apr 11; 98(4):1463-75. PubMed ID: 18752304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.